The vessel maturation induced by CD93 blockade resulted in exciting downstream therapeutic benefits—subcutaneous melanoma and pancreatic tumors had decreased growth, improved efficacy of chemotherapy delivery, and increased influx in anti-tumor immune cells such as CD8 + T cells and natural killer cells synergizing the effect of immunotherapy. This evidence concerns the gene CD93 and neoplasm.